PlainPharmaWatch

CMS Open Payments · Program Year 2024

Icometrix NV

Icometrix NV reported $67,000.00 across General Payments, Research, and Ownership to 26 physicians and teaching hospitals across 26 transactions.

$67.0K Below-median payer
All-tracks total
26 Below-median volume
Transactions
26 Below-median reach
Recipients
#1278
of 1,925 companies

Icometrix NV reported $67,000.00 across all CMS Open Payments tracks (General + Research + Ownership) to 26 physicians and teaching hospitals in Program Year 2024 - ranking #1278 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $67,000.00, averaging $2.6K per recipient.

Icometrix NV's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

10/100

Total payments

F

11/100

Transaction volume

F

10/100

Physician reach

F

10/100

Payment type diversity

F

10/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer icometrix-nv Icometrix NV

$67.0K · #1278/1,925 · 0.0% industry · PY2024

  • TOT $67.0K
  • RANK #1278
  • SHARE 0.0%
  • TXN 26
  • RCP 26
  • CAT 1
  • GEN $67.0K
  • TOP1 77.6%
  • PY 2024

Nearest volume peer: MIM Software Inc. ($67.1K)

Shimadzu Precision Instrumen…$67.9KImmunitybio, Inc.$67.8KMIM Software Inc.$67.1KIcometrix NV (this)$67.0KMomentis Surgical Inc.$66.7K
All-tracks payment totals near Icometrix NV (CMS Open Payments PY2024)

Icometrix NV sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Icometrix NV

CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Icometrix NV that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.

Of the 1 general-payment categories charted below, "Consulting Fee" is the largest at $67.0K across 26 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Icometrix NV made 1 types of general payments. "Consulting Fee" is the largest category at $67.0K, 100.0% of General Payments.

How Icometrix NV divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$67.0K
Payment Type Amount Transactions
Consulting Fee $67.0K 26

Recipient Concentration in General Payments

The five largest recipient relationships account for $67,000.00 (100.0%) of $67,000.00 in this company's General Payments records across 3 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Icometrix NV

The five named recipients with the highest reported General Payments from this company

Lawrence N Tanenbaum$52.0KMax Wintermark$12.0KMartin Niethammer$3.0K
  1. 1

    Lawrence N Tanenbaum

    $52,000.00 across 13 reported transactions

  2. 2

    Max Wintermark

    $12,000.00 across 12 reported transactions

  3. 3

    Martin Niethammer

    $3,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Icometrix NV ranks #1278 of 1,925 by total payments (bottom 34% by spend) but is notably more concentrated than that alone would suggest -- #252 of 1,838 by HHI (top 14% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.

00.00.00.00.16238.36302.96367.56432.16496.8Total payments ($M)Concentration (HHI, 0-10,000)
Icometrix NV (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Icometrix NV's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Icometrix NV.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Icometrix NV.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Icometrix NV ranks #1278 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Icometrix NV's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.